- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
20 result(s) found for: Swelling capacity.
Displaying page 1 of 1.
EudraCT Number: 2013-001616-30 | Sponsor Protocol Number: 000071 | Start Date*: 2013-09-17 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing a... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DK (Completed) ES (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004236-38 | Sponsor Protocol Number: 12250 | Start Date*: 2017-01-24 |
Sponsor Name:University of Oxford | ||
Full Title: OPtimising Treatment for MIld Systolic hypertension in the Elderly: a randomised controlled trial | ||
Medical condition: Hypertension | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2014-005323-27 | Sponsor Protocol Number: IM101-344 | Start Date*: 2015-09-16 | ||||||||||||||||
Sponsor Name:University of Michigan | ||||||||||||||||||
Full Title: A phase II study to evaluate subcutaneous abatacept vs. placebo in diffuse cutaneous systemic sclerosis—a double-blind, placebo-controlled, randomized controlled trial | ||||||||||||||||||
Medical condition: Diffuse Cutaneous Systemic Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-000152-11 | Sponsor Protocol Number: D3250R00107 | Start Date*: 2022-10-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) PT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000900-41 | Sponsor Protocol Number: WB28850 | Start Date*: 2013-05-10 |
Sponsor Name:F. Hoffmann-La Roche, Ltd. | ||
Full Title: A STUDY TO MEASURE SERUM PERIOSTIN, ASTHMA-RELATED BIOMARKERS AND RESPONSE TO PREDNISOLONE IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ORAL CORTICOSTEROID-DEPENDENT ASTHMA | ||
Medical condition: Severe corticosteroid-dependent asthma | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-002666-47 | Sponsor Protocol Number: SOAP1 | Start Date*: 2017-11-02 | |||||||||||
Sponsor Name:Dpt. of Ophthalmology, Rigshospitalet-Glostrup | |||||||||||||
Full Title: Effect of drop-less surgery compared to topical NSAID alone and combination of steroid and NSAID on central macular thickness after cataract surgery, a randomized controlled trial | |||||||||||||
Medical condition: Postoperative cystoid macular edema following cataract surgery | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000841-22 | Sponsor Protocol Number: HZA107112 | Start Date*: 2015-08-04 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: A randomised, double-blind, two-way crossover study to investigate the effect of inhaled fluticasone furoate on short-term growth in paediatric subjects with asthma | |||||||||||||
Medical condition: Chronic disease of the lungs characterized by airway inflammation, bonchoconstriction and increased airway responsiveness. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000633-36 | Sponsor Protocol Number: 000009 | Start Date*: 2011-08-09 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, controlled, assessor-blind, parallel groups, multinational, multicentre trial assessing the dose-response relationship of FE 999049 in controlled ovarian stimulation in women undergoi... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) CZ (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000890-29 | Sponsor Protocol Number: Destro | Start Date*: 2011-03-28 | |||||||||||
Sponsor Name:FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | |||||||||||||
Full Title: Instrumental and clinical effects of withdrawal of beta blockers therapy in patients with heart failure and right ventricular dysfunction'' | |||||||||||||
Medical condition: heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003453-34 | Sponsor Protocol Number: 201755 | Start Date*: 2015-06-18 | |||||||||||
Sponsor Name:GlaxoSmithKline Research & Development Limited | |||||||||||||
Full Title: A Phase IIb, Double-Blind, Placebo-Controlled, Dose-Adaptive, Study of the Efficacy and Safety of GSK3196165 in Combination with Methotrexate Therapy, in Subjects with Active Moderate-Severe Rheuma... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) GB (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002076-39 | Sponsor Protocol Number: WC42759 | Start Date*: 2022-02-25 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BALOVAPTAN IN PATIENTS WITH ACUTE ISCHEMIC STROKE AT HIGH RISK OF DEVELOPING MALIG... | |||||||||||||
Medical condition: Acute Ischemic Stroke (AIS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003337-34 | Sponsor Protocol Number: HZA106853 | Start Date*: 2012-03-06 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: HZA106853: A dose-ranging study of vilanterol (VI) inhalation powder in children aged 5-11 years with asthma on a background of inhaled corticosteroid therapy. | |||||||||||||
Medical condition: Children aged 5-11 years with persistent uncontrolled asthma | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) Outside EU/EEA PL (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004558-44 | Sponsor Protocol Number: 2021-00604 | Start Date*: 2021-10-10 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:UMCG | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Optimal Booster Strategy for SARS-CoV-2 Vaccination in Kidney Transplant patients | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: COVID-19 is associated with severely increased morbidity and mortality in kidney transplant patients. Available data show that the immune response after a standard regimen of two mRNA vaccinations ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001516-30 | Sponsor Protocol Number: GDX-44-007 | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:GUERBET | ||||||||||||||||||
Full Title: Pharmacokinetics, safety and efficacy of a new gadolinium-based contrast agent, gadopiclenol, in pediatric patients from 2 to 17 years of ageundergoing contrast-enhanced MRI. | ||||||||||||||||||
Medical condition: Pediatric subjects from 2 to 17 years old scheduled to undergo routine gadolinium contrast enhanced Magnetic Resonance Imaging of Central Nervous System | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SK (Ongoing) PL (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-000753-80 | Sponsor Protocol Number: 000298 | Start Date*: 2022-08-04 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: A randomised, assessor-blind, active-controlled, parallel-group, dose-finding trial to investigate the efficacy and safety of FE 999302 for triggering of final follicular maturation in women underg... | |||||||||||||
Medical condition: Infertility | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) CZ (Prematurely Ended) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003338-15 | Sponsor Protocol Number: HZA106855 | Start Date*: 2012-04-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: HZA106855: A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma. | |||||||||||||
Medical condition: Chronic disease of the lungs characterized by airway inflammation, bronchoconstriction and increased airway responsiveness. | |||||||||||||
|
|||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) Outside EU/EEA PL (Completed) LV (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004915-38 | Sponsor Protocol Number: V114-017 | Start Date*: 2018-10-04 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six M... | |||||||||||||
Medical condition: Pneumococcal disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003653-26 | Sponsor Protocol Number: OVG2011/07 | Start Date*: 2011-12-08 | |||||||||||
Sponsor Name:Clinical Trials and Research Governance | |||||||||||||
Full Title: A phase II, single-centre, randomised, single-blind, study to evaluate Vi-CRM197 against historical unvaccinated controls in a healthy adult challenge model, with a Vi-PS vaccine control arm. | |||||||||||||
Medical condition: Prophylaxis for Salmonella enterica serovar Typhi (S. Typhi) disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-014735-20 | Sponsor Protocol Number: MI-CP219 | Start Date*: 2009-12-29 | |||||||||||
Sponsor Name:MedImmune Ltd | |||||||||||||
Full Title: A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Efficacy and Safety of CAM-3001 in Subjects with Rheumatoid Arthritis | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) EE (Completed) HU (Completed) CZ (Completed) LT (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005514-40 | Sponsor Protocol Number: BO-001 | Start Date*: 2008-10-08 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Universitätslehrkrankenhaus Hall in Tirol | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Endothelin Receptor Blockade in Heart Failure with Diastolic Dysfunction and Pulmonary Hypertension Randomisierte, placebokontrollierte, multizentrische, doppel- blinde Pilotstudie zur Untersuchu... | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Heart failure with normal left ventricle systolic function (HFNEF) are common causes of hospitalisation mainly in the elderly population and are frequently associated with pulmonary hypertension. I... | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
